ResMed launches home COPD treatment
ResMed (ASX:RMD) has launched a new in-home treatment device for chronic obstructive pulmonary disease (COPD) in the US.
The Australia-founded company has secured the first FDA approval for a home variable positive airway pressure (VPAP) device to treat COPD and other respiratory disorders.
ResMed’s VPAP COPD is designed to be used at night to help COPD patients maintain ventilation while they are sleeping, preventing air trapping in the lungs.
The device can be wirelessly connected to the company’s cloud-based EasyCare online monitoring system, allowing healthcare providers to remotely monitor a patient’s respiratory health and response to home treatment.
An estimated one in five patients with stage 3 or 4 COPD hospitalised for acute exacerbations have to be re-admitted within 30 days. The system allows patients to continue treatment and be monitored during this 30-day window.
ResMed specialises in products to treat sleep-disordered breathing. New CEO Mick Farrell has revealed that the company plans to launch a second product this quarter and another new product by the end of calendar 2013.
The company overnight reported a record net profit of US$84.9 million ($82.3 million) for the first quarter - up 31% year on year.
ResMed shares were trading 1.22% lower at $4.445 as of around 1 pm on Friday.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
